These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 24356481)

  • 1. Effect of golimumab on carotid atherosclerotic disease measures and cardiovascular events in inflammatory arthritides.
    Wasko MC; Hsia EC; Kirkham B; Touboul PJ; Fleischmann R; Genovese MC; Matteson EL; Lu J; Xu W; Rahman MU
    J Clin Rheumatol; 2014 Jan; 20(1):1-10. PubMed ID: 24356481
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Golimumab: in the treatment of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
    Oldfield V; Plosker GL
    BioDrugs; 2009; 23(2):125-35. PubMed ID: 19489653
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial.
    Smolen JS; Kay J; Doyle MK; Landewé R; Matteson EL; Wollenhaupt J; Gaylis N; Murphy FT; Neal JS; Zhou Y; Visvanathan S; Hsia EC; Rahman MU;
    Lancet; 2009 Jul; 374(9685):210-21. PubMed ID: 19560810
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: results through 2 years of the GO-FORWARD study extension.
    Keystone EC; Genovese MC; Hall S; Miranda PC; Bae SC; Palmer W; Wu Z; Xu S; Hsia EC
    J Rheumatol; 2013 Jul; 40(7):1097-103. PubMed ID: 23678153
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study.
    Kay J; Matteson EL; Dasgupta B; Nash P; Durez P; Hall S; Hsia EC; Han J; Wagner C; Xu Z; Visvanathan S; Rahman MU
    Arthritis Rheum; 2008 Apr; 58(4):964-75. PubMed ID: 18383539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravenous golimumab is effective in patients with active rheumatoid arthritis despite methotrexate therapy with responses as early as week 2: results of the phase 3, randomised, multicentre, double-blind, placebo-controlled GO-FURTHER trial.
    Weinblatt ME; Bingham CO; Mendelsohn AM; Kim L; Mack M; Lu J; Baker D; Westhovens R
    Ann Rheum Dis; 2013 Mar; 72(3):381-9. PubMed ID: 22661646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Golimumab, a new human anti-tumor necrosis factor alpha antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study.
    Kremer J; Ritchlin C; Mendelsohn A; Baker D; Kim L; Xu Z; Han J; Taylor P
    Arthritis Rheum; 2010 Apr; 62(4):917-28. PubMed ID: 20131276
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Five-year Safety Data from 5 Clinical Trials of Subcutaneous Golimumab in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis.
    Kay J; Fleischmann R; Keystone E; Hsia EC; Hsu B; Zhou Y; Goldstein N; Braun J
    J Rheumatol; 2016 Dec; 43(12):2120-2130. PubMed ID: 27803138
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of golimumab on patient-reported outcomes in rheumatoid arthritis: results from the GO-FORWARD study.
    Genovese MC; Han C; Keystone EC; Hsia EC; Buchanan J; Gathany T; Murphy FT; Wu Z; Parasuraman S; Rahman MU
    J Rheumatol; 2012 Jun; 39(6):1185-91. PubMed ID: 22505702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GO-DACT: a phase 3b randomised, double-blind, placebo-controlled trial of GOlimumab plus methotrexate (MTX) versus placebo plus MTX in improving DACTylitis in MTX-naive patients with psoriatic arthritis.
    Vieira-Sousa E; Alves P; Rodrigues AM; Teixeira F; Tavares-Costa J; Bernardo A; Pimenta S; Pimentel-Santos FM; Gomes JL; Aguiar R; Pinto P; Videira T; Catita C; Santos H; Borges J; Sequeira G; Ribeiro C; Teixeira L; Ávila-Ribeiro P; Martins FM; Canhão H; McInnes IB; Ribeiro RM; Fonseca JE
    Ann Rheum Dis; 2020 Apr; 79(4):490-498. PubMed ID: 32193187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. E-selectin, interleukin 18, serum amyloid a, and matrix metalloproteinase 9 are associated with clinical response to golimumab plus methotrexate in patients with active rheumatoid arthritis despite methotrexate therapy.
    Visvanathan S; Wagner C; Rojas J; Kay J; Dasgupta B; Matteson EL; Mack M; Baker DG; Rahman MU
    J Rheumatol; 2009 Jul; 36(7):1371-9. PubMed ID: 19487269
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of golimumab, an anti-tumour necrosis factor-α human monoclonal antibody, on lipids and markers of inflammation.
    Kirkham BW; Wasko MC; Hsia EC; Fleischmann RM; Genovese MC; Matteson EL; Liu H; Rahman MU
    Ann Rheum Dis; 2014 Jan; 73(1):161-9. PubMed ID: 23300117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of golimumab on radiographic progression in rheumatoid arthritis: results of randomized controlled studies of golimumab before methotrexate therapy and golimumab after methotrexate therapy.
    Emery P; Fleischmann R; van der Heijde D; Keystone EC; Genovese MC; Conaghan PG; Hsia EC; Xu W; Baratelle A; Beutler A; Rahman MU
    Arthritis Rheum; 2011 May; 63(5):1200-10. PubMed ID: 21305524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of intravenous golimumab on health-related quality of life in rheumatoid arthritis: 24-week results of the phase III GO-FURTHER trial.
    Bingham CO; Weinblatt M; Han C; Gathany TA; Kim L; Lo KH; Baker D; Mendelsohn A; Westhovens R
    J Rheumatol; 2014 Jun; 41(6):1067-76. PubMed ID: 24786931
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of Methotrexate on Carotid Intima-media Thickness in Patients with Rheumatoid Arthritis.
    Kim HJ; Kim MJ; Lee CK; Hong YH
    J Korean Med Sci; 2015 Nov; 30(11):1589-96. PubMed ID: 26539002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Golimumab 3-year safety update: an analysis of pooled data from the long-term extensions of randomised, double-blind, placebo-controlled trials conducted in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis.
    Kay J; Fleischmann R; Keystone E; Hsia EC; Hsu B; Mack M; Goldstein N; Braun J; Kavanaugh A
    Ann Rheum Dis; 2015 Mar; 74(3):538-46. PubMed ID: 24344160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Golimumab: Review of the efficacy and tolerability of a recently approved tumor necrosis factor-α inhibitor.
    Boyce EG; Halilovic J; Stan-Ugbene O
    Clin Ther; 2010 Sep; 32(10):1681-703. PubMed ID: 21194591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Carotid atherosclerosis, disease measures, oxidized low-density lipoproteins, and atheroprotective natural antibodies for cardiovascular disease in early rheumatoid arthritis -- an inception cohort study.
    Ajeganova S; de Faire U; Jogestrand T; Frostegård J; Hafström I
    J Rheumatol; 2012 Jun; 39(6):1146-54. PubMed ID: 22589258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: 52-week results of the GO-FORWARD study.
    Keystone E; Genovese MC; Klareskog L; Hsia EC; Hall S; Miranda PC; Pazdur J; Bae SC; Palmer W; Xu S; Rahman MU
    Ann Rheum Dis; 2010 Jun; 69(6):1129-35. PubMed ID: 20444749
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Maintenance of efficacy and safety with subcutaneous golimumab among patients with active rheumatoid arthritis who previously received intravenous golimumab.
    Taylor PC; Ritchlin C; Mendelsohn A; Baker D; Kim L; Xu Z; Mack M; Kremer J
    J Rheumatol; 2011 Dec; 38(12):2572-80. PubMed ID: 22089463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.